- Gerd Burmester: EULAR/ACR recommendations in JAK inhibitors
- Johannes Bijlsma: Difficult to treat RA
- Ronald van Vollenhoven: Can JAK inhibitors become first-line therapy for RA? Pros and Cons
Forum Live
Expert perspectives on hot topics in rheumatology. Join world leading experts as they discuss the cutting-edge research influencing your clinical practice.